- Home
- BCV vs CRDF Comparison
BCV vs CRDF Comparison
Compare BCV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCV | CRDF |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.9M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BCV | CRDF |
|---|---|---|
| Price | $22.47 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.63 |
| AVG Volume (30 Days) | 26.3K | ★ 868.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.09 | $1.90 |
| 52 Week High | $18.11 | $5.64 |
Technical Indicators
Market Signals| Indicator | BCV | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 63.72 |
| Support Level | $21.96 | $2.09 |
| Resistance Level | $22.83 | $2.49 |
| Average True Range (ATR) | 0.34 | 0.14 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 79.66 | 83.33 |
Price Performance
Historical ComparisonAbout BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.